Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects.

about

Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects.

Item

http://www.wikidata.org/entity/Q50751188

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacodynamic properties and ...... healthy Chinese male subjects.

@en

Pharmacodynamic properties and ...... healthy Chinese male subjects.

@nl

type

Item

label

Pharmacodynamic properties and ...... healthy Chinese male subjects.

@en

Pharmacodynamic properties and ...... healthy Chinese male subjects.

@nl

prefLabel

Pharmacodynamic properties and ...... healthy Chinese male subjects.

@en

Pharmacodynamic properties and ...... healthy Chinese male subjects.

@nl

P1476

Pharmacodynamic properties and ...... healthy Chinese male subjects.

@en

P2093

Lijin Yu

http://www.w3.org/2001/XMLSchema#string

Ren Guo

http://www.w3.org/2001/XMLSchema#string

Sujie Jia

http://www.w3.org/2001/XMLSchema#string

Xin Guo

http://www.w3.org/2001/XMLSchema#string

Yuanyuan Xiang

http://www.w3.org/2001/XMLSchema#string

Zhigang Ding

http://www.w3.org/2001/XMLSchema#string

P2860

Dalteparin versus Unfractionated Heparin in Critically Ill Patients

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Current drug treatment strategies for disseminated intravascular coagulation.

FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer

Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients

Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency

Monitoring therapeutic anticoagulation with low molecular weight heparins: is it useful or misleading?

Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.

Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.

P304

376-381

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00498254.2017.1316021

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28375032

http://www.w3.org/2001/XMLSchema#string